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Complex IComplex I (CI) deﬁciency is a frequent cause of mitochondrial disorders and, in most cases, is due to muta-
tions in CI subunit genes encoded by mitochondrial DNA (mtDNA). In this study, we establish the pathogenic
role of the heteroplasmic mtDNA m.3890G>A/MT-ND1 (p.R195Q) mutation, which affects an extremely con-
served amino acid position in ND1 subunit of CI. This mutation was found in a young-adult male with optic
atrophy resembling Leber's hereditary optic neuropathy (LHON) and bilateral brainstem lesions. The only
previously reported case with this mutation was a girl with fatal infantile Leigh syndrome with bilateral
brainstem lesions. Transfer of the mutant mtDNA in the cybrid cell system resulted in a marked reduction
of CI activity and CI-dependent ATP synthesis in the presence of a normally assembled enzyme.
These ﬁndings establish the pathogenicity of the m.3890G>A/MT-ND1 mutation and remark the link be-
tween CI mutations affecting the mtDNA-encoded ND subunits and LHON-like optic atrophy, which may be
complicated by bilateral and symmetric lesions affecting the central nervous system. Peculiar to this muta-
tion is the distribution of the brainstem lesions, with sparing of the striatum in both patients.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Mitochondrial complex I (NADH: ubiquinone oxidoreductase, CI,
EC:1.6.5.3) is the ﬁrst energy-transducing enzyme of the mitochon-
drial respiratory chain. By oxidizing NADH and transferring electrons
to the ﬁnal acceptor ubiquinone coupled with proton translocation
across the mitochondrial inner membrane, CI contributes to generate
the mitochondrial membrane potential utilized to produce ATP
through the process of oxidative phosphorylation (OXPHOS) [1]. CIComplex III; CIV, Complex IV;
chondrial DNA; nDNA, nuclear
ght eye)
e Neurologiche, Dipartimento
Bologna, Via Altura 3, 40139
092751.
-NC-ND license.is a large multi-subunit respiratory enzyme built assembling seven
ND subunits encoded by mitochondrial DNA (mtDNA) and about 38
subunits encoded by nuclear DNA (nDNA). Thus, this is the only re-
spiratory enzyme with such a large component dependent on
mtDNA and, considering the high mutation rate of this small circular
genome, over the last 20 years an increasing number of pathogenic
mutations has been described in association with human diseases [2].
Historically, the ﬁrst nucleotide changes affecting ND subunits of
complex I have been associated with Leber's hereditary optic neurop-
athy (LHON, OMIM 535000) [3–5]. Currently, three common patho-
genic point mutations m.11778G>A/MT-ND4, m.3460G>A/MT-ND1
and m.14484T>C/MT-ND6 are found in over 90% of LHON cases
worldwide [6]. Syndromic forms of LHON-like optic atrophy and
basal ganglia lesions or stroke-like episodes have been also associated
with severe pathogenic mutations in ND subunit genes, linking in a
continuum LHON with Leigh syndrome (LS), bilateral striatal necrosis
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stroke-like episodes (MELAS) [6]. These phenotypes may coexist in
the same maternal lineage in relation with different tissue loads of
heteroplasmic mutation, thus indicating different thresholds for clin-
ical phenotypes. Examples of well-established mutations with vari-
able phenotype are the m.14459G>A/MT-ND6 mutation associated
with LHON and spastic dystonia, or the m.13513G>A/MT-ND5 muta-
tion associated with LHON and MELAS, both also reported as causing
infantile LS [6].
We here report the second patient carrying the heteroplasmic mu-
tation m.3890G>A/MT-ND1 (p.R195Q), a young adult affected with
LHON-like severe optic neuropathy and bilateral, partially reversible,
lesions of the brainstem [7]. By transferring the mutant mtDNA in
transmitochondrial cytoplasmic hybrid (cybrid) cells we established
the pathogenic role of this mutation, which affects CI function in
homoplasmic mutant cybrids.Fig. 1. Brain MRI: (A) 31-year-old, FLAIR T2-weighted axial image shows bilateral and sy
T2-weighted axial image shows increased volume and increased signal intensity of the rig
hypointense signal changes of both inferior colliculi (arrows), consistent with cystic nec
color pictures of the patient at 3 years follow-up. OCT shows a diffuse thinning of RNFL t
the optic disc at fundus pictures (D).2. Materials and methods
2.1. Case report
The proband is a 35 years oldmale who suffered, when hewas 31, a
sudden and painless loss of vision in OS and, after twoweeks, in OD. The
patient reported blurring of the central vision associated with
photopsias, and a ﬁrst ophthalmologic exam showed hyperemic optic
disc with teleangectatic vessels in the absence of ﬂuorescein leakage
at ﬂuorangiography. Pattern visual evoked potentials (PVEPs) revealed
abnormal morphology with normal latency of cortical responses in OD
and absent responses in OS. Hewas treatedwith corticosteroids and vi-
tamin B12 without any beneﬁt. Three months later a second ophthal-
mologic exam reported that initial temporal pallor of the optic disc
and visual acuity was decreased to 1/20 both eyes with bilateral
cecocentral scotoma.mmetrical hyperintensities of the vestibular nuclei (arrows); (B) 33-year-old, FLAIR
ht inferior colliculus (arrow); (C) 35-year-old, FSPGR-T1-weighted axial image shows
rotic lesions. OCT analysis of RNFL thickness (Cirrus, Carl Zeiss Meditec) and fundus
hickness corresponding to complete atrophy of the optic nerve as shown by pallor of
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based on a preceding history of recurrent abdominal pain and diarrhea
complained by the patient since the age of 29, and recurrent oral
aphtae and joints pain since he was 14. Three months before visual
loss the patient presented persistent vertigo and brainMRI showed bi-
lateral and symmetrical focal hyperintensities on T2-weighted images
affecting the vestibular nuclei (Fig. 1A). These abnormalities were
completely resolved at an MRI scan performed 3 months later, at the
time of visual loss, with only evidence of a mild left optic nerve
hyperintensity on T2-weighted images. Thus, on the basis of clinical
and neuroradiological presentation, although all blood and cerebro-
spinal ﬂuid tests for autoimmune disorders were normal, a diagnosis
of Bechet vasculitis with central nervous system involvement was
postulated and a therapy with corticosteroids and cyclosporine was
started without beneﬁts.
We observed this patient 9 months after the onset of vision loss. At
the ophthalmologic exam he showed bilateral severe reduction of visual
acuity (counting ﬁnger in both eyes), cecocentral scotoma and bilateral
temporal optic disc pallor. The infero-temporal retinal nerve ﬁber layer
thickness was reduced in both eyes at the optical coherence tomography
(OCT). The neurological exam showed mild bilateral postural tremor at
upper limbs, brisk deep tendon reﬂexes with right rotuleus and achilles
clonus. Autoimmune and celiac screeningswere negative. PVEPs showed
the absence of cortical responses bilaterally. Electromyography identiﬁed
slight myopathic changes. Somatosensorial andmotor evoked potentials
were normal. The standard genetic screening for the three common
mtDNA LHON mutations (m.11778G>A/MT-ND4, m.3460G>A/MT-ND1
and m.14484T>C/MT-ND6) was negative. Idebenone therapy was
started after 10 months from the onset of visual loss (405 mg/day).
At 33 years of age the patient complained of recurrent tinnitus in
the right ear and underwent a new brain MRI that showed, on
T2-weighted images, increased signal intensity of the right inferior
colliculus that was of increased volume without post-contrast en-
hancement (Fig. 1B). The brain MRI performed for follow-up at the
age of 35 years showed signal changes (hyperintensities on
T2-weighted and hypointensity on T1-weighted images) affecting
both inferior colliculi consistent with bilateral necrotic cystic lesions,Fig. 2. Brain proton MR spectroscopy: (A) mild pathological accumulation of lactate was
288 ms) in the cerebrospinal ﬂuid of the lateral ventricles (B). Venous serum lactate in LHO
topathology: H&E, COX/SDH and SDH stains show some variability of ﬁber caliber and sligh
muscle is normalized for citrate synthase (CS) activity (E). Asterisks indicate statistical signand the normalization of the volume of the right inferior colliculus
(Fig. 1C), in the absence of brainstem, cerebellar or cerebral atrophy.
Over the last 3 years OCT analysis showed a progressive thinning
of the retinal nerve ﬁber layer thickness in all quadrants (Fig. 1D)
with pale optic discs bilaterally at fundus exam and further reduction
of the patient visual function. He continued on therapy with
idebenone (540 mg/day) without any subjective or measurable im-
provement of visual acuity.
2.2. Muscle, biochemical and magnetic resonance
spectroscopy investigations
Venous serum lactatewasmeasured by a standardized exercise pro-
tocol, as previously detailed [8], in the proband and, for comparison, in a
cohort of twenty LHON patients with one of the three canonical
mutations.
Proton Magnetic Resonance Spectroscopy (1H-MRS) and skeletal
muscle phosphorusMagnetic Resonance Spectroscopy (31P-MRS) stud-
ies were carried out on a 1.5-T whole body magnet (Signa Horizon
General ElectricsMedical SystemsMilwaukee,Wisconsin).MRS investi-
gationswere performed in order to assess the bioenergetics of brain and
skeletal muscle. Brain single voxel 1H-MRS was performed using the
point resolved spectroscopy sequence. In order to maximize the detec-
tion of lactate, a volume of interest was selected in the lateral ventricles
to include mostly the CSF (TE=288, TR=1500, number of acquisi-
tions=384) [9]. Suppressed water spectra were pre-processed with
Gaussian ﬁltering of 2 Hz followed by exponential ﬁltering of −1 Hz,
and lactate ﬁtted by the time domain semi-parametric algorithm
QUEST. Skeletal muscle 31P -MRS was performed under resting condi-
tions, as well as during an aerobic exercise and after recovery, as previ-
ously described [10]. A sample of 15 healthy volunteers age-matched
was also studied with the same protocol.
Tibialis anterior muscle biopsy was carried out after informed con-
sent of the patient. Histological and histoenzymatic analysis including
hematoxylin & eosin (H&E) staining, cytochrome oxidase (COX) ac-
tivity, succinic dehydrogenase (SDH) activity and double COX/SDH
staining were performed [11].detected by 1H-MRS (single voxel PRESS localization sequence, TR=1500 ms, TE=
N patients (n=20) and in the proband (normal range 5.8–22 mg/dl) (C). Muscle his-
t subsarcolemmal increase of SDH (D). Respiratory chain complexes activity in skeletal
iﬁcance (pb0.05).
Table 1
All mtDNA changes in patient's complete mtDNA sequence (GenBank ID JQ408982)
compared to the Cambridge Reference Sequence (rCRS, GenBank ID NC_012920). All
changes, except m.3890G>A, are reported as neutral [39].
Nucleotide differences relative to rCRS Gene Amino-acid change
m.263A>G MT-DLOOP –
m.315insC MT-DLOOP –
m.750A>G MT-RNR1 –
m.961T>C MT-RNR1 –
m.1438 A>G MT-RNR1 –
m.3010G>A MT-RNR2 –
m.3890G>A MT-ND1 p.R195Q
m.4769A>G MT-ND2 Synonymous
m.7765A>G MT-CO2 Synonymous
m.8860A>G MT-ATP6 p.Y112A
m.13836A>G MT-ND5 Synonymous
m.15326A>G MT-CYB p.Y194A
m.16519T>C MT-DLOOP –
Fig. 3. Quantiﬁcation of the m.3890G>A/MT-ND1 mutation load by ARMS qPCR (A) in
proband's skeletal muscle, blood cells and urinary epithelium, and in family (B) mem-
bers' urinary epithelium, expressed as % of mutant 3890A compared to wild-type (wt)
3890G. The arrow indicates the proband, while asterisks indicate family members who
were investigated.
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enates were assessed with a dual-wavelength spectrophotometer
(V550 Jasco Europe, Italy) in a stirred cuvette at 37 °C containing
50mMKH2PO4 (pH 7.6) 1 mM EDTA. CI activity (NADH:DB oxidore-
ductase) was assessed in the presence of 0.3 mM KCN, 50 μM DB
and 100 μM NADH (λ 340–380 nm; εNADH: 6.2 mM−1 cm−1), after
subtraction of 1 μM rotenone-insensitive activity. CII+CIII (succi-
nate:cytochrome c oxidoredutase) and CIII (DBH2:cytochrome c
oxidoreductase) activities were measured following the antimycin
A sensitive reduction of cytochrome c (λ: 550–540 nm; εcyt c=
19.1 mM−1 cm−1) in presence of 0.3 mM KCN, 40 μM cytochrome
c, 10 mM succinate or 50 μM DBH2. The CIV activity was determined
adding 60 μM of reduced bovine heart cytochrome c, after subtraction
of 0.3 mM KCN-insensitive activity. Data were corrected for citrate
synthase activity and protein content [12,13].
2.3. Mitochondrial DNA analysis
Total DNA was extracted by standard methods from blood cells,
urinary sediment epithelium and skeletal muscle after informed con-
sent and approval of the internal review board. Direct sequence anal-
ysis of the entire mtDNA molecule was performed on total DNA
extracted from skeletal muscle, as previously reported [14]. The
m.3890G>A/MT-ND1 mutation was conﬁrmed by restriction frag-
ment length polymorphism (RFLP) analysis (primers and conditions
are available upon request).
2.4. Quantiﬁcation of the m.3890G>A/MT-ND1 mutation load by real
time ampliﬁcation refractory mutation system (ARMS) quantitative PCR
The ARMS qPCR assay was performed with a LightCycler® 480
Real-Time PCR System (Roche) using SYBR Green chemistry, according
to published procedures [15]. Primers were designed introducing two
mismatches, according to Bai and Wong [16]. The primer sequences
used were as follows: ARMS forward primer for wild-type m.3890G:
5′-CACACTAGCAGAGACCAAggG-3′; ARMS forward primer for mutant
m.3890A: 5′-CACACTAGCAGAGACCAAggA-3′; ARMS reverse primer:
5′-TGTGTATTCGGCTATGAAGAATAGG-3′, which is common for both
wild-type and mutant alleles; forward primer for total mtDNA:
5′-CCCTAAAACCCGCCACATCT-3′; reverse primer for total mtDNA:
5′-GAGCGATGGTGAGAGCTAAGGT-3′. The lowercase letter in the prim-
er indicates a mismatch nucleotide being introduced to increase the
primer speciﬁcity [16]. The percentage of mutation heteroplasmy was
calculated by absolute quantiﬁcation through calibration curves gener-
ated by serial dilutions of the target sequence PCR products. Two differ-
ent mtDNA amplicons were produced and inserted in a pGEM-T Easy
Vector (Promega). The two plasmids contained respectively 3890G
(wild-type) and 3890A (mutant), both encompassing the entire
MT-ND1gene sequence.
2.5. Cybrids studies
Cybrid cell lines were generated from patient's skin ﬁbroblasts
(heteroplasmic with about 50% mutant load) as previously described
[17]. Cybrids were grown in Dulbecco's modiﬁed Eagle medium
(DMEM) supplemented with 10% fetal calf serum (South America
source from Gibco, Invitrogen, Italy), 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, in an incubator with a humidiﬁed
atmosphere of 5% CO2 at 37 °C. For cell viability experiments, cells
(4×104 cells/cm2) were seeded in 24 well plates and incubated for
different times in glucose-free DMEM supplemented with 5 mmol/L
galactose, 5 mmol/L Na-pyruvate and 5% FBS (DMEM-galactose). Via-
bility was determined using the colorimetric sulforhodamine B assay
[18], by measuring the sulforhodamine B absorbance at 570 nm with
a VICTOR3 Multilabel Plate Counter (PerkinElmer Life and Analytical
Sciences, Zaventem Belgium).The rate of mitochondrial ATP synthesis wasmeasured in digitonin-
permeabilized cybrids using the previously described luciferin/
luciferase assay [19], withminormodiﬁcations [20]. The rateswere nor-
malized to protein content and citrate synthase activity [12,13].
Isolation of mitochondrial-enriched fraction was carried out essen-
tially as previously described [21]. Respiratory chain complexes activi-
ties were performed in 50 mM KH2PO4 buffer (pH 7.6), 3,5 mg/ml
BSA and 20 μg of mitochondrial protein. CI activity (NADH:DB:DCIP ox-
idoreductase) was assessed in the presence of 60 μM DCIP (λ 600 nm;
εDCIP: 19.1 mM−1 cm−1), 70 μM DB and 200 μM NADH, as previously
described [21], after subtraction of 1 μM rotenone-insensitive activity.
CI+CIII activity (NADH:cytochrome c reductase) was performed fol-
lowing cytochrome c reduction in the presence of 200 μM NADH and
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and 1 μM antimycin A-insensitive activity. The CIII activity was deter-
mined as the antimycin A-sensitive DBH2:cytochrome c reductase activ-
ity, in the presence of 50 μMDBH2 and 20 μMbovine heart cytochrome
c, as previously described [22]. CIV activitywasmeasured adding 20 μM
of reduced bovine heart cytochrome c, essentially as described in ref.
[22]. The rates were normalized to citrate synthase activity and protein
content [12,13]. CI assembly and in-gel activity were determined after
Blue-Native electrophoresis of isolated mitochondria as previously de-
scribed [23].
2.6. Statistical analysis
Data are presented as means±SD. Statistical signiﬁcance, deter-
mined by the Student t test for unpaired data, was considered atFig. 4. Global alignment of ND1 protein sequences from a wide range of eukaryotes and proka
and 79.9% are highlighted in light gray, those between 80.0% and 99.9% are highlighted in dark g
ND1mutations in a bi-dimensional model (B). Note that most of the trans-membrane domains
which affect complex I activity (C). Bi-dimensional representation of EF loop with bacterial mup≤0.05. When data were not normally distributed the Mann–Whitney
test was applied.
3. Results
3.1. Evidence of mitochondrial dysfunction with CI defect
Brain 1H-MRS, performed 9 months after onset of vision loss,
disclosed a mild pathological accumulation of lactate, in the lateral
ventricles, conﬁrmed 2 years later by a second brain 1H-MRS exam
(Fig. 2A–B). Muscle 31P-MRS failed to show abnormalities of energy
metabolism either at rest or after aerobic exercise. Notwithstanding
this, two independent assessments of serum venous lactate after
standardized exercise and after recovery showed a persistently ele-
vated lactic acid in the proband (after exercise 60.0±19.2 mg/dl;ryotes (A). Amino acid residues with a percentage of conservation ranging between 70.0%
ray and those invariant (100%) are highlighted in black. Localization of human pathogenic
are free frommutations. Table of bacterial mutations versus human positions, in EF loop,
tations (D). The bacteria residue R209 corresponds to R195 in human.
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was signiﬁcantly higher compared to the levels measured by the
same protocol in a cohort of LHON patients (n=20) carrying one of
the canonical mutations (Fig. 2C).
Muscle histology (H&E) and histoenzymatic stains (COX, SDH and
COX/SDH) showed minimal changes with ﬁbers size variability and
increased subsarcolemmal SDH (Fig. 2D). Assessment of respiratory
chain activities on skeletal muscle homogenate revealed that CI was
50% reduced compared to controls (proband 8.04±0.70 nmol/min
mg, controls 16.05±1.80 nmol/min mg) (Fig. 2E). Non-signiﬁcant
differences were observed for the integrated CII+CIII activity,
which was increased in the proband, and CIII activity, which was
reduced in the proband; CIV activity was normal (Fig. 2E).
3.2. Mitochondrial DNA analysis and protein modeling
Based on the LHON-like phenotype, the brain pathological accu-
mulation of lactate at 1H-MRS, the pathologically high serum lactic
acid after exercise, the reduction of CI activity in muscle, and having
excluded the three common mutations associated with LHON we
completely sequenced the proband's mtDNA. This resulted in the
detection of the previously reported non-synonymous transition
at position m.3890G>A/MT-ND1 [7] on a haplogroup H1 back-
ground (GenBank ID JQ408982) (Table 1) [24]. The quantiﬁcation
of the m.3890G>A/MT-ND1 mutation load by ARMS qPCR in differ-
ent tissues showed that it was almost homoplasmic in the skeletal
muscle and heteroplasmic, with different mutational loads, in
blood cells and urinary epithelium (Fig. 3A). The mutation was
also found in the proband's unaffected mother, with a substantially
lower mutant load, and was absent in the other maternal relatives
(Fig. 3A–B).
The m.3890G>A/MT-ND1 mutation changes a basic arginine
with a polar glutamine at the highly conserved amino acid position
195 (p.R195Q) in the ND1 subunit of CI (Fig. 4A). As shown in Fig. 4B
this residue is located in the extra-membrane loop EF, which is also
affected by the amino acid substitutions p.E214K and p.Y215H,Fig. 5. Activity of respiratory chain complexes normalized for citrate synthase (CS) activity
bation in galactose medium (C) and ATP synthesis rates normalized for CS activity (D) in
(100%) for m.3890G>A/MT-ND1 mutation. Asterisks indicate statistical signiﬁcance (*pb0.respectively caused by the MELAS pathogenic mutations m.3946G>A
and m.3949T>C [25]. In Fig. 4C and D all the mutations studied in the
EF loop of the bacterial subunit corresponding to ND1 are reported.
They are all associated with a decreased NADH-oxidation activity
(40–98% of reduction), a partial CI disassembly and, in particular, the
substitutions corresponding to p.E214K and p.Y215H abolished the
membrane potential generated by the respiratory chain [26–28].
3.3. Cybrids studies
To assess the causal pathogenic role of the m.3890G>A/MT-ND1
mutationwe generated cybrid cell lines, by transferring only the patient
mtDNA into the rhomtDNA-devoid recipient cells, derived from the os-
teosarcoma143B.TK-cell line. After cybridizationwe selected for further
studies three syngeneic clones differing only at the np 3890, one
homoplasmic wild type, one 50% heteroplasmic and one homoplasmic
mutant. The CI redox activity was reduced in both heteroplasmic and
homoplasmic mutant cybrids, but only the homoplasmic mutant
clone showed a signiﬁcant decrease (~50%) compared to wild-type
(Fig. 5A). In addition, the CI+CIII integrated activity revealed a
non-signiﬁcant decrease in both heteroplasmic and homoplasmic mu-
tant clones, whereas CIII activity was not affected, indicating a defective
function limited to the respiratory CI (Fig. 5A). Complex IV activity was
normal in all clones (Fig. 5A). Furthermore,we investigated the possible
role played by the 3890G>A homoplasmic mutation on CI assembly.
The in-gel-activity after BN-gel electrophoresis showed that this muta-
tion did not affect the assembly of CI (Fig. 5B). We also assessed the
overall mitochondrial energetic function by growing the cybrid clones
in a glucose-free medium containing galactose. Under these conditions,
the rate of glycolysis is markedly reduced and cells are forced to use ox-
idative phosphorylation for ATP production [29]. After 48 hours incuba-
tion in DMEM-galactose medium, the number of viable homoplasmic
mutant cybrids was signiﬁcantly reduced (~75%) compared to the
wild-type or the heteroplasmic clones (Fig. 5C). Furthermore, the rate
of mitochondrial ATP synthesis driven by CI substrates (pyruvate/
malate) was signiﬁcantly reduced in both the heteroplasmic (~20%)(A), CI in-gel-activity (B), indicated by an arrow, time course of cell viability after incu-
three syngeneic cybrid clones: wild-type (0%), heteroplasmic (50%) and homoplasmic
05; **pb0.001).
451L. Caporali et al. / Biochimica et Biophysica Acta 1832 (2013) 445–452and homoplasmic (~50%) mutant cell lines, whereas the rate of ATP
synthesis with the complex II substrate (succinate) was unaffected
(Fig. 5D).
4. Discussion
This study reports the second patient carrying the m.3890G>A/
MT-ND1 mutation, characterized by a complex I defect in muscle
and LHON-like severe optic atrophy associated with bilateral
brainstem lesions. Our results, obtained by transferring the mutant
mtDNA from heteroplasmic ﬁbroblasts into cybrids, after selecting
mtDNA isogenic clones except for the m.3890G>A/MT-ND1 mutant
position, establish the pathogenic role of this rare mutation in affect-
ing CI function.
The previously reported patient carrying the m.3890G>A/
MT-ND1 mutation presented an early-onset severe encephalopathy
leading to death at about 3 years of age. The clinical diagnosis was
of Leigh syndrome, due to the occurrence of bilateral lesions in the
subthalamic nuclei, lower pons and brainstem [7]. Respect to this
case, our patient presented a milder phenotype consisting in a severe
form of LHON-like visual loss with onset in adult age and without
other major clinical manifestations in the 4 years of follow-up. Sim-
ilarly to the other case, he developed bilateral and symmetrical focal
alterations affecting the brainstem, hyperintense on T2-weighted
images. These brain MRI abnormalities ﬁrstly involved the vestibular
nuclei and were associated with transient episodes of vertigo,
disappearing along with the symptoms after a few months. Subse-
quently, other lesions with similar characteristics involved the infe-
rior colliculi, in association with recurrent tinnitus, evolving in
necrotic cavities.
The presence of MR alterations and corresponding neuropathologi-
cal changes in different structures of brainstem, including the inferior
colliculi, are well recognized in LS, in association with lesions located
in the basal ganglia and/or diencephalon [30]. On the other hand, a
few patients, carrying the common LHON mutations or the
m.11777C>A/MT-ND4mutation affecting the same amino acid position
of the LHON mutation m.11778/MT-ND4 (p.R340H) with a different
amino acid change (p.R340S), presented bilateral brainstem lesions
[31,32]. A recent study reviewing a large cohort of LS patients suggested
that brainstem lesions are more typical for mtDNA-related complex I
deﬁciency, in most cases with the concurrent striatal involvement
[33]. Peculiar to both patients carrying them.3890G>A/MT-ND1muta-
tion is the sparing of the striatum. Furthermore, in our patient the neu-
roradiological evolution also recalls the cerebral lesions characterizing
the stroke-like episodes in MELAS syndrome, which can fully resolve
or leave residual MRI abnormalities [34]. However, reversibility of the
brain lesion has also been documented in LS [30].
Overall, our patient differed from the previous one for a milder phe-
notype. Optic atrophy was the main clinical feature of our patient, re-
sembling a severe version of LHON. It is of note that the initial
diagnostic hypothesis of Bechet vasculitis with central nervous system
involvement delayed the identiﬁcation of mitochondrial dysfunction
as the pathogenic mechanism for optic neuropathy. However, the typi-
cal hallmarks of a mitochondrial optic neuropathy, with preferential in-
volvement of the papillomacular bundle, with central scotoma and
initial temporal pallor, re-directed the diagnosis towards LHON, leading,
by complete mtDNA sequence analysis, to the identiﬁcation of the rare
m.3890G>A/MT-ND1 mutation. The OXPHOS impairment associated
with this mutation was more severe than normally seen in LHON, as
documented by higher values of serum lactic acid levels and pathologi-
cal presence of lactic acid in the ventriculi at brain 1H− MRS. This im-
pairment was associated with a virtually homoplasmic mutant mtDNA
in the skeletal muscle and about 50% mutational load in blood cells.
The previously reported patient had 95%mutant mtDNA in the skeletal
muscle [7]. Thus, based on these results it is difﬁcult to state that differ-
ences in clinical severity between the two patients are clearly ascribedto a different heteroplasmic load of the mutation in cerebral tissue. Nu-
clear modifying genes may also be involved in modulating the severity
of mtDNA mutations affecting ND subunits of complex I.
The cybrid cell model has been exploited to characterize the patho-
logic features of the m.3890G>A/MT-ND1 mutation, which affects a
highly conserved region of the ND1 subunit of CI. As recently demon-
strated by X-ray crystallographic studies on CI from T. thermophilus,
the ND1 subunit forms the interface between the two arms of CI, the
hydrophobic membrane and the hydrophilic matrix-protruding re-
gions [35]. Furthermore, the ND1 subunit most probably participates
in forming the quinone-binding pocket together with the nuclear-
encoded subunits NDUFS7 and NDUFS2 [36]. The 3D structure of the
bacterial CI has been completely resolved, with the only remarkable ex-
ception of the ND1 subunit, for which only the overall number of trans-
membrane helices is available [37]. The extra-membrane domains of
ND1, constituted by more than 100 amino acids, are essential for CI
function and structure, as demonstrated by the presence of numerous
pathogenic mutations in mitochondrial patients. Compatibly, the
m.3890G>A/MT-ND1mutation decreased CI redox activity and CI driv-
en ATP synthesis, without affecting CI assembly, as studied in patient's
mutant cybrids. Interestingly, other mutations in the same region of
ND1 subunit have been reported in patients affected by MELAS and
optic atrophy [2,6]. Noticeably, the CI activity, as well as the CI-driven
ATP synthesis were also affected in the heteroplasmic cybrid clone
(50% mutant) suggesting the absence of a clear cut threshold, as fre-
quently seen for other mtDNA pathogenic mutations [38]. Thus, this
mutation seems to be rate limiting on the CI-driven ATP synthesis.
However, the parallel pathway through CII may function as compensa-
tory, as suggested by the tendency to increased CII+CIII activity seen
in both proband's muscle and mutant cybrids, and unaffected CII-
substrate driven ATP synthesis in mutant cybrids.
5. Conclusions
In this study we identiﬁed the m.3890G>A/MT-ND1 (p.R195Q) mu-
tation in a patient affected by LHON-like optic atrophy and bilateral
brainstem lesions. This mutation, absent from population surveys and
public datasets of more than ten thousand complete mtDNAs (GenBank
database was searched onMarch 2nd 2012), was previously detected in
a patient with fatal infantile LS with bilateral brainstem lesions [7]. The
conservation analysis of the corresponding amino acid position and the
functional characterization of cybrid cells carrying the mutant mtDNA
compared to syngeneic wild-type cybrids provided evidence on the
pathogenic role of thismutation clearly compromising the function of CI.
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